Q2 2025 Axsome Therapeutics Inc Earnings Call Transcript
Key Points
- Axsome Therapeutics Inc (AXSM) reported total revenue of $150 million for the second quarter, marking a substantial 72% year-over-year increase and a 24% sequential growth.
- The company successfully launched SYMBRAVO, its third approved product, into the acute migraine market, with encouraging early feedback from the migraine community.
- Auvelity and Sunosi demonstrated strong performance, with Auvelity generating approximately 192,000 prescriptions in Q2, representing 15% quarter-over-quarter growth and 56% year-over-year growth.
- Axsome Therapeutics Inc (AXSM) expanded market access for Auvelity, adding approximately 28 million new covered lives in the commercial channel, increasing coverage to 83% of lives across all channels.
- The company is advancing multiple late-stage development programs, including AXS-05 for Alzheimer's disease agitation and AXS-12 for narcolepsy, with significant progress towards regulatory submissions expected in the fourth quarter.
- Despite the revenue growth, Axsome Therapeutics Inc (AXSM) reported a net loss of $48 million for the second quarter, although this was an improvement from the previous year's loss.
- The gross-to-net discounts for Auvelity and Sunosi remained high, in the mid-50s range, which could impact profitability.
- SYMBRAVO's initial gross-to-net was in the low 80% range, indicating significant discounts and rebates impacting early revenue recognition.
- Research and development expenses remained high at $49.5 million, reflecting ongoing investment in clinical trials and development programs.
- The company faces competitive challenges in the market, particularly in the ADHD and migraine segments, where new treatments and existing options may impact market share.
Good morning, and welcome to the Axsome Therapeutics second quarter 2025 financial results conference call. (Operator Instructions) Please note this call is being recorded.
I would now like to turn the call over to Darren Opland, Director of Corporate Communications at Axsome Therapeutics. Please go ahead.
Thank you, and good morning, everyone. Thank you all for joining us for our second quarter 2025 earnings call. With me today are Dr. Herriot Tabuteau, our Chief Executive Officer; Nick Pizzie, our Chief Financial Officer; and Ari Maizel, our Chief Commercial Officer, who will begin our call with prepared remarks. Mark Jacobson, our Chief Operating Officer; and Hunter Murdock, our General Counsel, will join us for the Q&A portion of the call.
This morning, we issued our earnings press release providing a business update and details of the company's financial results for the second quarter of 2025. I encourage everyone to visit the Investors page of our website
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
